Editorial
Emerging roles of FGF signaling in hepatocellular carcinoma
Translational Cancer Research
2016;
5
(1)
:1-6
.
(01 February 2016)
HER2 as a therapeutic target in gallbladder cancer—aye or nay?
Translational Cancer Research
2016;
5
(1)
:7-10
.
(01 February 2016)
Expanding landscape of CDKN1A (p21) functions: CDKN1A-mediated radioresistance of dermal Langerhans cells and its impact on the immune system
Translational Cancer Research
2016;
5
(1)
:11-13
.
(01 February 2016)
Activated status of Hedgehog pathway in oral squamous cell carcinoma (OSCC): the door is still open
Translational Cancer Research
2016;
5
(1)
:14-16
.
(01 February 2016)
Postoperative treatment for head and neck cancer: the emerging role of EGFR-targeted therapy
Translational Cancer Research
2016;
5
(1)
:17-19
.
(01 February 2016)
Original Article
Use of yttrium-90 radioembolization for patients with unresectable liver metastases: experience from a single center
Translational Cancer Research
2016;
5
(1)
:20-29
.
(01 February 2016)
Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Translational Cancer Research
2016;
5
(1)
:30-35
.
(01 February 2016)
Hyponatremia in small cell lung cancer is associated with a poorer prognosis
Translational Cancer Research
2016;
5
(1)
:36-43
.
(01 February 2016)
Brief Report
Extracellular matrix in gene expression profiling of cancer
Translational Cancer Research
2016;
5
(1)
:44-48
.
(01 February 2016)
Review Article
Protein kinase CK2 in DNA damage and repair
Translational Cancer Research
2016;
5
(1)
:49-63
.
(01 February 2016)
Commentary
Natural (tryptophan) metabolites—mediated activation of aryl hydrocarbon receptor inhibits cancer stem cell signaling: what does it mean to prevent cancer recurrence?
Translational Cancer Research
2016;
5
(1)
:64-67
.
(01 February 2016)
“Boom-Boom” radioimmunotherapy of lymphomas: are two magic bullets better than one?
Translational Cancer Research
2016;
5
(1)
:68-71
.
(01 February 2016)
Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma
Translational Cancer Research
2016;
5
(1)
:72-74
.
(01 February 2016)
Irradiation and combination immunotherapy
Translational Cancer Research
2016;
5
(1)
:75-78
.
(01 February 2016)
A circadian prelude to regulation of angiogenesis and thrombosis by prolactin and plasminogen activator inhibitor-1
Translational Cancer Research
2016;
5
(1)
:79-82
.
(01 February 2016)
Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma
Translational Cancer Research
2016;
5
(1)
:83-84
.
(01 February 2016)
Correspondence
Role of season in overall survival of patients with bone metastasis undergoing radiotherapy
Translational Cancer Research
2016;
5
(1)
:85-88
.
(01 February 2016)
